Status:
UNKNOWN
Role of Co-trimoxazole in Severe COVID-19 Patients
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Collaborating Sponsors:
Anwar Khan Mordern Medical College and Hospital, Dhaka
Mugda Medical College and Hospital, Dhaka
Conditions:
Covid19
Severe COVID-19 Patients
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Coronavirus Disease 19 (COVID-19) is a global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Severe disease occurs in 15% of the cases with COVID-19 and may progress ...
Detailed Description
Coronavirus disease (COVID-19) caused by SARS-COV2, represents a highly transmissible and potentially fatal disease that is of great global public health concern at this moment. The pandemic situation...
Eligibility Criteria
Inclusion
- Diagnosed COVID-19 patients ( RT-PCR positive for COVID-19)
- Age \> 18 years
- Hypoxic respiratory failure (saturation \<90% on air at rest or increasing oxygen requirement)
- Chest examination findings of bilateral crackles on auscultation or chest x-ray showing bilateral infiltrates
- C-Reactive Protein \> 50mg/L
Exclusion
- Multi-organ failure
- Severe ARDS (requiring ventilator support on presentation in the form of invasive or non-invasive ventilation)
- Septic Shock
- Severe liver disease
- Acute Kidney Injury (where GFR\< 15 and plasma-sulfamethoxazoleconcentration cannot be monitored)
- Drug allergy/intolerance to co-trimoxazole / Sulphar sensitivity
- Pregnancy
- Already receiving Tocilizumab or convalescent therapy
Key Trial Info
Start Date :
July 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2021
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04470531
Start Date
July 12 2020
End Date
January 30 2021
Last Update
July 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1200